Apellis Pharmaceuticals, Inc. (APLS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Group 1 - The launch of the product is proceeding as planned by the commercial team, indicating effective execution and strategy [1] - The disease C3G and IC-MPGN is rare, making it challenging to identify the patient population and unmet needs across various nephrologists [1] - The company's business intelligence and commercial team have successfully established the epidemiology of the disease and the potential patient base [1]